NCT00645866View on ClinicalTrials.gov

Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Breast Cancer
Interventions
DRUG

capecitabine

DRUG

docetaxel

DRUG

epirubicin hydrochloride

OTHER

laboratory biomarker analysis

OTHER

pharmacogenomic studies

PROCEDURE

biopsy

PROCEDURE

neoadjuvant therapy

PROCEDURE

therapeutic surgical procedure

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER